Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 1997

View Archived Issues

Spiro compounds for CNS disorders disclosed by Takeda

U.S. and European investigators describe agents for CNS disorders

ET antagonists reported by Japanese investigators

Takeda prepares NO production inhibitors

Sankyo develops antidiabetic agents

Eisai synthesizes heterocyclic anticancer compounds

Hypoglycemic/hypolipidemic agents from Kyorin

Sumitomo develops ACAT inhibitors

Diagnostic MAbs from Terumo

Update on GEM-91

Potent gpIIb/IIIa antagonist synthesized using combinatorial techniques

U.S. patent issued for meningococcal B vaccine

Selective gelatinase inhibitor described by British Biotech

Tanabe selects ellipticine derivative for further development

Potent dual CCK-A/CCK-B antagonist discovered by Japanese researchers

Genzyme Transgenics reports advances in transgenic production of MAbs

Merck & Co. and Costa Rican institute renew biological diversity agreement

U.S. researchers report significant advance in gene therapy for hearing disorders

ChemTrak colorectal cancer home test ready for launch

Essential fatty acids in schizophrenia

Cangene awarded ISO registration

Remune associated with chemokine induction

U.K. launch for SKB anticancer treatment

Positive phase III trials results for citicoline

Tretinoin gel cleared for marketing by FDA

T Cell Sciences awarded second grant for vaccine development

Sparta expands clinical trials of retinoid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...